Conference icon

Conference

Preservation of recall immunity in anti-CD3-treated recent onset type 1 diabetes patients.

Abstract:

BACKGROUND: The safety of any immune modulating agent in type 1 diabetes mellitus (T1DM) involves its selectivity on autoimmunity and its preservation of recall and tumour immunity. METHODS: We performed lymphocyte proliferation tests on seven recent onset diabetic patients treated with anti-CD3 (Otelixizumab; ChAglyCD3) and five recent onset diabetic patients treated with placebo, on average 2 years after therapy. RESULTS: Proliferative responses towards common viral, bacterial and yeast an...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1002/dmrr.1273

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Pathology Dunn School
Role:
Author
Expand authors...
Volume:
27
Issue:
8
Pages:
925-927
Publication date:
2011-11-05
DOI:
EISSN:
1520-7560
ISSN:
1520-7552
URN:
uuid:68c9823a-c957-4280-9669-a6adc46eaae8
Source identifiers:
314350
Local pid:
pubs:314350

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP